Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Bristol Myers sees return to growth for Opdivo, tops estimates

07/28/2021 | 08:11am EDT
FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge

(Reuters) - Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter.

Excluding one-time items, Bristol Myers reported earnings of $4.3 billion, or $1.93 per share, beating analyst estimates of around $4.2 billion and $1.89 per share, according to IBES data from Refinitiv.

Bristol Myers reported second quarter revenues of $11.7 billion, 16% higher than in the same period last year, driven in part by sales of Opdivo that exceeded $1.9 billion for the quarter, 16% higher than in the quarter ended June 30, 2020.

"The highlight that is driving that strong performance is Opdivo and its return to growth," said David Elkins, Bristol-Myers' chief financial officer.

Opdivo revenues benefitted from approvals in new tumor types and its increasing use as an initial treatment for advanced lung cancer, Elkins said.

Bristol Myers' second quarter results mark a reversal from its performance last year, where a 3% decline in sales of Opdivo contributed to lower-than-expected earnings.

Bristol Myers still expects full-year earnings in the range of $7.35 to $7.55 a share

In the second quarter, Bristol Myers announced two deals with biotechs Agenus Inc and Eisai Co to develop and market new cancer drugs and it expects to do additional deals to build out its portfolio of medicines, Elkins said.

"With the financial flexibility we have, we are really focusing on replenishing and diversifying the portfolio," Elkins said. He added that Bristol Myers is more likely to engage in deals for individual products as opposed to large scale corporate M&A.

Revlimid, the blockbuster cancer drug Bristol Myers acquired in its $74 billion deal for Celgene in 2019, will lose some of its U.S. patent exclusivity in 2022, putting pressure on the company to add new products to its pipeline.

The COVID-19 pandemic continues to affect Bristol Myers but the drugmaker saw a significant improvement in the second quarter in many of its businesses, said Chief Commercial Officer Chris Boerner.

(Reporting by Carl O'Donnell; editing by Richard Pullin)

By Carl O'Donnell

© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
AGENUS INC. -4.14% 5.09 Delayed Quote.60.06%
BRISTOL-MYERS SQUIBB COMPANY -2.43% 56.94 Delayed Quote.-8.21%
Latest news "Economy & Forex"
05:55aIndonesia central bank keeps rates at record lows amid tentative recovery
05:51aChina Evergrande makes onshore coupon payment - sources
05:51aIndonesia c.bank keeps rates at record lows amid tentative recovery
05:50aRussian communications regulator roskomadzor says will seek fine on google's turnover this month
05:50aFine could be as high as $240 mln, according to reuters calculations and figures from russian companies database
05:50aRussian communications regulator roskomadzor says fine relates to repeated failure to delete content moscow deems illegal
05:47aExplainer-Is China finally ready to roll out a property tax?
05:45aBitcoin on cusp of all-time high ahead of futures ETF listing
05:39aEUROPE GAS-Prices mixed on stronger demand, profit taking
05:39aECB's Rehn warns of risk from lengthy inflation surge
Latest news "Economy & Forex"